Hepatocellular Carcinoma
Conditions
Keywords
Hepatocellular carcinoma, Hepatoma, HCC
Brief summary
This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis. Treatment will be assessed for adverse effects and for effects on the tumor.
Detailed description
This is a multicenter, open-label, non-randomized, dose-escalation study, to be conducted in 2 phases: a dose-escalation phase, to determine the MTD of CF102 and to evaluate its safety/tolerability, PK, pharmacodynamic, and preliminary clinical activity; and a dose-confirmation phase, which will be a cohort expansion at or below the MTD (ie, the RP2D) of CF102. Subjects will be treated with oral doses of CF102 in consecutive, 28-day cycles. The initial dose of CF102 will be 1 mg twice daily (BID), with subsequent escalations to 5 and 25 mg BID, unless limited by toxicity. Subjects will be evaluated weekly for the first cycle, every 2 weeks for Cycles 2 and 3, and at the end of each subsequent cycle, up to 6 cycles of CF102 treatment. Subjects will return for a follow-up visit 28 days after completion of the last dose of study drug.
Interventions
DRUGCF102
CF102 capsules twice daily by mouth
Sponsors
Can-Fite BioPharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Study Arms: CF102 (1, 5, and 25 mg BID) in 28-day cycles.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of HCC: * For patients without underlying cirrhosis, diagnosis of HCC documented by cytology and/or histology * For patients with underlying cirrhosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Appendix V). 2. HCC is advanced, refractory, or metastatic, and no standard therapies are expected to be curative. 3. At least 18 years of age. 4. For subjects in the dose-confirmation (RP2D) phase only: Measurable disease, using Response Evaluation Criteria in Solid Tumors (RECIST, Appendix IV). (Note that a lesion that has been subjected to radiotherapy or chemoembolization cannot be used as a target lesion.) 5. Eastern Collaborative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at baseline. 6. The following laboratory values must be documented within 3 days prior to initiation of study drug: * Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L * Platelet count greater than or equal to 50 x 109/L * Serum creatinine less than or equal to 2.0 mg/dL * Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal. * Total bilirubin ≤ 3.0 mg/dL. * Serum albumin ≥ 3.0 g/dL. * International normalized ratio (INR) ≤ 2.3. 7. Esophageal bleeding and varices, if present, have been sclerosed or banded, and no bleeding episodes have occurred during the prior 6 months. 8. Life expectancy of ≥ 12 weeks. 9. For women of childbearing potential, negative serum pregnancy test result. 10. Absence of active malignancy other than HCC within 2 years of entry, with the exception of basal cell carcinoma and squamous cell carcinoma of the skin. 11. Provide written informed consent to participate. 12. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study related procedures. \-
Exclusion criteria
1. Any chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, corticosteroids \> 20 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug. 2. Major surgery or radiation therapy within 28 days prior to initiation of study drug. 3. Severe liver dysfunction (Child-Pugh Class C or hepatic encephalopathy). 4. Active infection requiring systemic therapy. 5. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug. 6. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to \> 450 msec for males or \> 470 msec for females. 7. Pregnant or lactating female. 8. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Principal Investigator (PI), are effective and adequate for that patient's circumstances while on study drug. 9. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug. 10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness. 11. Any severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity | From start of treatment until Day 28 of Cycle 1 | Dose-limiting toxicity was defined as a clinically significant AE or laboratory abnormality occurring in Cycle 1 |
| Maximum Tolerated Dose | first 28 days (Cycle 1) | The MTD was defined as the highest dose level at which \< 2 of 6 patients developed Cycle 1 DLT. |
| Maximum Plasma Concentration of CF102 (Cmax) | Dose Escalation Phase on Day 1 and Day 29 pre-dose and at 1, 2, 3, 4, 6, 8 hours post-dose | Blood samples were collected and plasma concentrations determined using a high-pressure liquid chromatography method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With Objective Tumor Response | 6 months | Therapeutic effect of CF102 in hepatocellular carcinoma measured by number of subjects with objective tumor response |
| Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102 | Baseline to Day 28 | The Peripheral Blood Mononuclear Cells (PBMC) were to be collected at Baseline and Day 28 in order to evaluate the Adenosine A3 receptor (A3AR) and PBMC biomarkers, and clinical effects of CF102. |
Countries
Israel
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| CF102 CF102: CF102 capsules twice daily by mouth | 19 |
| Total | 19 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | CF102 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 12 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants |
| Region of Enrollment Israel | 19 participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 6 / 6 | 6 / 6 | 7 / 7 |
| serious Total, serious adverse events | 3 / 6 | 6 / 6 | 3 / 7 |
Outcome results
Primary
Dose Limiting Toxicity
Dose-limiting toxicity was defined as a clinically significant AE or laboratory abnormality occurring in Cycle 1
Time frame: From start of treatment until Day 28 of Cycle 1
Population: Safety Population (all subjects receiving at least one dose of study drug)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CF102 1mg | Dose Limiting Toxicity | 0 Participants |
| CF102 5mg | Dose Limiting Toxicity | 0 Participants |
| CF102 25mg | Dose Limiting Toxicity | 0 Participants |
Primary
Maximum Plasma Concentration of CF102 (Cmax)
Blood samples were collected and plasma concentrations determined using a high-pressure liquid chromatography method.
Time frame: Dose Escalation Phase on Day 1 and Day 29 pre-dose and at 1, 2, 3, 4, 6, 8 hours post-dose
Population: The first 3 subjects in each dosing cohort participated in the pharmacokinetic sampling.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CF102 1mg | Maximum Plasma Concentration of CF102 (Cmax) | Day 1 | 4.455 ng/mL | Standard Deviation 2.975 |
| CF102 1mg | Maximum Plasma Concentration of CF102 (Cmax) | Day 29 | 10.46 ng/mL | Standard Deviation 8.864 |
| CF102 5mg | Maximum Plasma Concentration of CF102 (Cmax) | Day 1 | 25.10 ng/mL | Standard Deviation 16.93 |
| CF102 5mg | Maximum Plasma Concentration of CF102 (Cmax) | Day 29 | 53.69 ng/mL | Standard Deviation 31.76 |
| CF102 25mg | Maximum Plasma Concentration of CF102 (Cmax) | Day 1 | 98.36 ng/mL | Standard Deviation 22.6 |
| CF102 25mg | Maximum Plasma Concentration of CF102 (Cmax) | Day 29 | 330.6 ng/mL | Standard Deviation 61.17 |
Primary
Maximum Tolerated Dose
The MTD was defined as the highest dose level at which \< 2 of 6 patients developed Cycle 1 DLT.
Time frame: first 28 days (Cycle 1)
Population: All subjects were evaluated for DLTs in the first cycle of therapy.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CF102 1mg | Maximum Tolerated Dose | NA milligrams |
| CF102 5mg | Maximum Tolerated Dose | NA milligrams |
| CF102 25mg | Maximum Tolerated Dose | NA milligrams |
Secondary
Number of Subjects With Objective Tumor Response
Therapeutic effect of CF102 in hepatocellular carcinoma measured by number of subjects with objective tumor response
Time frame: 6 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CF102 1mg | Number of Subjects With Objective Tumor Response | 0 Participants |
| CF102 5mg | Number of Subjects With Objective Tumor Response | 0 Participants |
| CF102 25mg | Number of Subjects With Objective Tumor Response | 0 Participants |
Secondary
Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102
The Peripheral Blood Mononuclear Cells (PBMC) were to be collected at Baseline and Day 28 in order to evaluate the Adenosine A3 receptor (A3AR) and PBMC biomarkers, and clinical effects of CF102.
Time frame: Baseline to Day 28
Population: No data was collected for this exploratory endpoint.